Modification of morphine-induced hyperlocomotion and antinociception in mice by clorgyline, a monoamine oxidase-A inhibitor

Neurochemical Research

Volumn 31, Issue 6, 2006, Pages 829-837

  Kitanaka, Nobue ^a   Kitanaka, Junichi ^a   Takemura, Motohiko ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Antinociception; Clorgyline; Hyperlocomotion; Monoamine turnover; Morphine; Striatum

Indexed keywords

BRAIN MONOAMINE; CLORGYLINE; MONOAMINE OXIDASE A INHIBITOR; MORPHINE; SODIUM CHLORIDE;

ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; HOT PLATE TEST; HYPERACTIVITY; LOCOMOTION; MALE; MEASUREMENT; MONOAMINE METABOLISM; MOTOR ACTIVITY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STEREOTYPY; TAIL FLICK TEST;

ANALGESICS; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLORGYLINE; LOCOMOTION; MALE; MICE; MICE, INBRED ICR; MONOAMINE OXIDASE INHIBITORS; MORPHINE;

EID: 33746331053     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-006-9087-x     Document Type: Article

References (33)

1. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383:819-823
2. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, Uhl GR (1997) Opiate receptor knockout mice define μ receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549
3. Uhl GR, Sora I, Wang Z (1999) The μ opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96:7752-7755
4. Johnson SW, North RA (1992) Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12:483-488
5. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274-5278
6. Mathon DS, Lesscher HM, Gerrits MA, Kamal A, Pintar JE, Schuller AG, Spruijt BM, Burbach JP, Smidt MP, van Ree JM, Ramakers GM (2005) Increased GABAergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in μ-opioid receptor knockout mice. Neuroscience 130:359-367
7. Contarino A, Picetti R, Matthes HW, Koob GF, Kieffer BL, Gold LH (2002) Lack of reward and locomotor stimulation induced by heroin in μ-opioid receptor-deficient mice. Eur J Pharmacol 446:103-109
8. Moles A, Kieffer BL, D'Amato FR (2004) Deficit in attachment behavior in mice lacking the μ-opioid receptor gene. Science 304:1983-1986
9. De Vries TJ, Shippenberg TS (2002) Neural systems underlying opiate addiction. J Neurosci 22:3321-3325
10. Gardner EL (2004) Brain reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds) Substance abuse: a comprehensive textbook, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 48-97
11. Kelley AE, Berridge KC (2002) The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306-3311
12. Nestler EJ, Berhow MT, Brodkin ES (1996) Molecular mechanisms of drug addiction: adaptations in signal transduction pathways. Mol Psychiat 1:190-199
13. Przewlocki R (2004) Opioid abuse and brain gene expression. Eur J Pharmacol 500:331-349
14. Wise RA (2002) Brain reward circuitry: insights from unsensed incentives. Neuron 36:229-240
15. Kitanaka N, Kitanaka J, Takemura M (2005) Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-A inhibitor, through alteration of the 5-hydroxytryptamine turnover in the striatum. Neuroscience 130:295-308
16. Kitanaka N, Kitanaka J, Takemura M (2005) Repeated clorgyline treatment inhibits methamphetamine-induced behavioral sensitization in mice. Neurochem Res 30:445-451
17. Kitanaka N, Sora I, Kinsey S, Zeng Z, Uhl GR (1998) No heroin or morphine 6β-glucuronide analgesia in μ-opioid receptor knockout mice. Eur J Pharmacol 355:R1-R3
18. Kitanaka N, Kitanaka J, Takemura M (2003) Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur J Pharmacol 474:63-70
19. Tatsuta T, Kitanaka N, Kitanaka J, Morita Y, Takemura M (2005) Effects of monoamine oxidase inhibitors on methamphetamine-induced stereotypy in mice and rats. Neurochem Res 30:1377-1385
20. Mori T, Ito S, Narita M, Suzuki T, Sawaguchi T (2004) Combined effects of psychostimulants and morphine on locomotor activity in mice. J Pharmacol Sci 96:450-458
21. Finberg JP, Youdim MB (1983) Selective MAO A and B inhibitors: their mechanism of action and pharmacology. Neuropharmacology 22:441-446
22. de Vries M, Odink J (1991) Simultaneous measurement of serotonin and 5-hydroxyindoleacetic acid in rat brain using a liquid chromatographic method with electrochemical detection. J Chromatogr 564:250-257
23. Felner AE, Waldmeier PC (1979) Cumulative effects of irreversible MAO inhibitors in vivo. Biochem Pharmacol 28:995-1002
24. 3-receptor agonist (±)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. Neurosci Lett 187:45-48
25. Segal DS, Kuczenski R, Okuda C (1992) Clorgyline-induced increases in presynaptic DA: changes in the behavioral and neurochemical effects of amphetamine using in vivo microdialysis. Pharmacol Biochem Behav 42:421-429
26. 2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 144:875-884
27. Itzhak Y, Stein I, Zhang S-H, Kassim CO, Cristante D (1991) Binding of σ-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of σ-receptor subtypes. J Pharmacol Exp Ther 257:141-148
28. 2 imidazoline-preferring receptors. Br J Pharmacol 114:837-845
29. Rane A, Gawronska-Sxklarz B, Svensson JO (1985) Natural (-)- and unnatural (+)-enantiomers of morphine: comparative metabolism and effect of morphine and phenobarbital treatment. J Pharmacol Exp Ther 234:761-765
30. King CD, Rios GR, Green MD, MacKenzie PI, Tephly TR (1997) Comparison of stably expressed UGT1.1 and UTG2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 25:251-255
31. Morland J, Jones BL, Palomares ML, Alkana RL (1994) Morphine-6- glucuronide: a potent stimulator of locomotor activity in mice. Life Sci 55:163-168
32. Lipkowski AW, Carr DB, Langlade A, Osgood PF, Szyfelbein SK (1994) Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci 55:149-154
33. Sharma U, Roberts ES, Hollenberg PF (1996) Formation of a metabolic intermediate complex of cytochrome P4502B1 by clorgyline. Drug Metab Dispos 24:1247-1253